On July 26, Tianxing Capital Investment Co., Ltd. and Yuanquantang signed the "Mutual Cooperation Agreement" and "Cooperation Area Agreement". The two sides carry out strategic cooperation on the development of Chinese medicine in line with the principles and objectives of "complementary advantages, mutual benefit, common development, and win-win cooperation".

By signing this agreement, the two parties will establish a close cooperation system and synergistically enhance the interests of both parties in the process of cooperation.

The cooperation between the two parties has the following contents:

· Development of human, material, other resources and information exchange required by the two companies;

· The activities of Yuanhetang Pharmaceutical Co., Ltd. into the Korean market and expanding its scale;

· Promotion of activities related to Yuanhetang Pharmaceutical Co., Ltd. in Korea.

This cooperation will have a positive impact on the business performance of the source and pharmaceutical industry, not only to enhance its brand influence, expand sales channels, but also enhance the company's profitability.